Search

Search Constraints

You searched for: Author/Creator Marmorino, F

Search Results

1. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (1st October 2019)

2. LBA-007Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC. (2nd July 2019)

3. LBA20TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts). (23rd October 2018)

4. O-013Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019)

5. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018)

6. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018)

7. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018)

8. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018)

9. PD-008Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting. (20th June 2018)

10. PD-008Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting. (20th June 2018)